Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Distinct effects on cAMP signaling of carbamazepine and its structural derivatives do not correlate with their clinical efficacy in epilepsy

Research output: Contribution to journalJournal articleResearchpeer-review

  1. The effects of CGRP in vascular tissue - Classical vasodilation, shadowed effects and systemic dilemmas

    Research output: Contribution to journalReviewResearchpeer-review

  2. CGRP in rat mesenteric artery and vein - receptor expression, CGRP presence and potential roles

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Gasotransmitters and the immune system: Mode of action and novel therapeutic targets

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. MR-vejledt laserablation til behandling af hjernetumorer og epilepsi

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. A high-resolution in vivo atlas of the human brain's benzodiazepine binding site of GABAA receptors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 7T Epilepsy Task Force Consensus Recommendations on the Use of 7T MRI in Clinical Practice

    Research output: Contribution to journalReviewResearchpeer-review

  4. Extensive astrocyte metabolism of γ-aminobutyric acid (GABA) sustains glutamine synthesis in the mammalian cerebral cortex

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sara Krarup
  • Christoffer Mertz
  • Emil Jakobsen
  • Sandy E H Lindholm
  • Lars H Pinborg
  • Lasse K Bak
View graph of relations

The antiepileptic sodium channel blocker, carbamazepine, has long been known to be able to attenuate cAMP signals. This could be of clinical importance since cAMP signaling has been shown to be involved in epileptogenesis and seizures. However, no information on the ability to affect cAMP signaling is available for the marketed structural derivatives, oxcarbazepine and eslicarbazepine acetate or their dominating metabolite, licarbazepine. Thus, we employed a HEK293 cell line stably expressing a cAMP biosensor to assess the effect of these two drugs on cAMP accumulation. We find that oxcarbazepine does not affect cAMP accumulation whereas eslicarbazepine acetate, surprisingly, is able to enhance cAMP accumulation. Since the transcription of ADCY8 (adenylyl cyclase isoform 8; AC8) has been found to be elevated in epileptic tissue from patients, we subsequently expressed AC8 in the HEK293 cells. In the AC8-expressing cells, oxcarbazepine was now able to attenuate whereas eslicarbazepine maintained its ability to increase cAMP accumulation. However, at all concentrations tested, licarbazepine demonstrated no effect on cAMP accumulation. Thus, we conclude that the effects exerted by carbamazepine and its derivatives on cAMP accumulation do not correlate with their clinical efficacy in epilepsy. However, this does not disqualify cAMP signaling per se as a potential disease-modifying drug target for epilepsy since more potent and selective inhibitors may be of therapeutic value.

Original languageEnglish
JournalEuropean Journal of Pharmacology
Volume886
Pages (from-to)173413
ISSN0014-2999
DOIs
Publication statusPublished - 5 Nov 2020

ID: 61289882